UKRI puts £80m into nine NHS technologies to speed up dementia diagnosis

UK Research and Innovation launched an £80 million Dementia Challenge on 2 October 2026, funding nine technologies and service changes meant to diagnose dementia faster inside the NHS ¹. The stated target is that 92% of people are diagnosed within 18 weeks of referral, against around 60% now ¹.

What the money buys

The nine funded projects mix imaging, digital assessment, AI and service redesign ¹:

• an MRI project that aims to cut scan times from around 20 minutes to around seven ¹;

• a digital platform built into the NHS that lets people track changes in their cognitive health ¹;

• a home-monitoring platform that uses sensors and linked AI ¹;

• a panel of blood-based biomarkers placed in routine NHS memory services ¹;

• a 15-minute remote digital cognitive assessment ¹;

• routine sleep apnoea screening for everyone referred to memory assessment services ¹;

• a test run on a standard home computer and headphones that assesses how the brain processes sound ¹;

• an AI-enabled decision support tool that predicts progression from routinely collected data such as medical records, blood tests and cognitive tests ¹;

• a redesign of dementia diagnosis and treatment services in Scotland, with 'living labs' for new biomarkers and treatments ¹.

Every project faces real-world assessment, and a 'fail-fast' clause means only those that are working can draw further money ¹. Science Minister Chris McDonald said the government is backing projects that can "spot the signs earlier" ¹.

One of the nine is identifiable from its developers. Imperial's Minder platform combines in-home sensor data with algorithms trained on seven years of data, for example predicting infection risk from heart and respiratory rate captured by an under-mattress sensor ². Its clinical service, MinderCare, runs inside the NW London virtual hospital with Imperial College Healthcare NHS Trust, sends reports into the electronic health record and is working on commissioning models with the NW London ICB ². Imperial says the work underpinned its successful bid, which includes adapting and testing MinderCare in rural and coastal settings with the Pears Cumbria School of Medicine ².

What it means for the market

The challenge is a staged buying signal rather than a single grant. Suppliers of remote cognitive testing, home sensing, blood biomarkers and AI decision support now have a funded route to prove performance in NHS settings, with continued money tied to results ¹. For memory services and ICBs, the 18-week target sets the yardstick these tools will be judged against ¹.

The size of the problem is the commercial case. Imperial puts the cost of dementia care in the UK at an estimated £42 billion a year, projected to reach £90 billion by 2040, and says around one in six hospital beds are occupied by someone living with dementia ². Dr Richard Oakley of the Alzheimer's Society said one in three people living with dementia in the UK do not have a diagnosis at any one time ¹.

Caveats

The source does not break down how the £80 million is split across the nine projects, name most of the lead organisations or set out the timetable for the fail-fast reviews ¹. The Minder figures come from Imperial's own account of its work, and its primary outcome measure, Days Alive and Out of Hospital, is still being assessed in the MinderCare study ².